EC
BDTX icon

EcoR1 Capital’s Black Diamond Therapeutics BDTX Stock Holding History

EcoR1 Capital’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,191,094
Closed -$2.25M – 56
2023
Q1 		$2.25M Buy
1,191,094
+908,963
+322% +$2.09M 0.07% 44
2022
Q4 		$508K Buy
+282,131
New +$508K 0.02% 64

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital's BDTX Position: Q2 2023 in Review

EcoR1 Capital sold out of Black Diamond Therapeutics (BDTX) in Q2 2023, closing a stake of 1,191,094 shares — an estimated $2.25M sold.

EcoR1 Capital first reported a position in BDTX in Q4 2022 and held it in 2 quarters. The position peaked at $2.25M in Q1 2023. 74 funds tracked by Wall St. Rank hold BDTX as of Q2 2023.

  • EcoR1 Capital reported no remaining Black Diamond Therapeutics position as of Q2 2023 after selling out during the quarter.
  • EcoR1 Capital sold 1,191,094 Black Diamond Therapeutics shares in Q2 2023, an estimated $2.25M.
  • EcoR1 Capital first reported a position in Black Diamond Therapeutics in Q4 2022 and held it in 2 quarters.
  • EcoR1 Capital's Black Diamond Therapeutics position peaked at $2.25M in Q1 2023.
  • 74 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2023.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.